Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
Superinvestors holding PCVX, Q2 2026
1 superinvestor reports holding Vaxcyte, Inc. on Form 13F, worth $93.8M in total. Weight is Vaxcyte, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Maverick CapitalLee Ainslie | 0.8% | 1,613,242 | $93.8M | Added+17.1% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of PCVX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+17.1%)
- Sold out
- Baupost Group
Q1 2026
2 superinvestors holding at quarter end
- New
- Baupost Group
- Added
- Maverick Capital (+1.7%)
Q4 2025
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+5.0%)
Q3 2025
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−1.6%)
Q2 2025
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+8.5%)
Q1 2025
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+0.5%)
- Sold out
- Duquesne Family Office
Q4 2024
2 superinvestors holding at quarter end
- Added
- Maverick Capital (+23.1%), Duquesne Family Office (+100.8%)
Q3 2024
2 superinvestors holding at quarter end
- New
- Duquesne Family Office
- Added
- Maverick Capital (+41.9%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+93.7%)
Q1 2024
1 superinvestor holding at quarter end